Skip to main content
Top

04-01-2025 | Cannabinoid | Current Opinion

The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors

Authors: Kelly A. Sagar, Staci A. Gruber

Published in: CNS Drugs

Login to get access

Abstract

The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e., non-medical) and medical purposes, it is critical to gain a deeper understanding of the ways in which cannabis may be helpful or harmful for those diagnosed with psychiatric disorders. Although cannabis is composed of hundreds of compounds, studies assessing the effects of “cannabis” most often report the impact of delta-9-tetrahydrocannabinol (d9-THC), the primary intoxicating constituent of the plant. While d9-THC has documented therapeutic properties, negative clinical outcomes commonly associated with cannabis are generally related to d9-THC exposure. In contrast, non-intoxicating cannabinoids such as cannabidiol (CBD) show promise as potential treatment options for psychiatric symptoms. In this article, findings from studies and reviews examining the relationship between mental health conditions (mood, anxiety, psychosis, and post-traumatic stress disorder [PTSD]) and cannabis use are summarized to highlight critical variables that are often overlooked, including those associated with cannabis use patterns (e.g., frequency of use, amount used, cannabinoid exposure, product choice, and route of administration). Further, this article explores individual factors (e.g., age, sex, genetics/family history) that likely impact cannabis-related outcomes. Research to date suggests that youth and those with a family history or genetic liability for psychiatric disorders are at higher risk for negative outcomes, while more research is needed to fully understand unique effects related to sex and older age.
Literature
1.
go back to reference Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based psychiatric benefits—a critical review. Pharmacopsychiatry. 2024;57:115–32.PubMedCrossRef Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based psychiatric benefits—a critical review. Pharmacopsychiatry. 2024;57:115–32.PubMedCrossRef
2.
go back to reference Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: adverse outcomes and self-reported impact of cannabis use by mental health status: substance use & misuse. Subst Use Misuse. 2022;57:719–29.PubMedCrossRef Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: adverse outcomes and self-reported impact of cannabis use by mental health status: substance use & misuse. Subst Use Misuse. 2022;57:719–29.PubMedCrossRef
4.
go back to reference Kuhns L, Kroon E, Colyer-Patel K, Cousijn J. Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence. Psychopharmacology. 2022;239:1231–49.PubMedCrossRef Kuhns L, Kroon E, Colyer-Patel K, Cousijn J. Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence. Psychopharmacology. 2022;239:1231–49.PubMedCrossRef
5.
go back to reference Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382: e072348.PubMedPubMedCentralCrossRef Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382: e072348.PubMedPubMedCentralCrossRef
6.
go back to reference Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, et al. Major phytocannabinoids and their related compounds: should we only search for drugs that act on cannabinoid receptors? Pharmaceutics. 2021;13:1823.PubMedPubMedCentralCrossRef Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, et al. Major phytocannabinoids and their related compounds: should we only search for drugs that act on cannabinoid receptors? Pharmaceutics. 2021;13:1823.PubMedPubMedCentralCrossRef
10.
go back to reference Donnan J, Shogan O, Bishop L, Swab M, Najafizada M. Characteristics that influence purchase choice for cannabis products: a systematic review. J Cannabis Res. 2022;4:9.PubMedPubMedCentralCrossRef Donnan J, Shogan O, Bishop L, Swab M, Najafizada M. Characteristics that influence purchase choice for cannabis products: a systematic review. J Cannabis Res. 2022;4:9.PubMedPubMedCentralCrossRef
12.
13.
go back to reference Lambros AM, Sagar KA, Dahlgren MK, Kosereisoglu D, El-Abboud C, Smith RT, et al. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure. Sci Rep. 2023;13: 5869.PubMedPubMedCentralCrossRef Lambros AM, Sagar KA, Dahlgren MK, Kosereisoglu D, El-Abboud C, Smith RT, et al. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure. Sci Rep. 2023;13: 5869.PubMedPubMedCentralCrossRef
14.
go back to reference Wright M, Di Ciano P, Brands B. Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5:191–6.PubMedPubMedCentralCrossRef Wright M, Di Ciano P, Brands B. Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5:191–6.PubMedPubMedCentralCrossRef
15.
go back to reference Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:51–64.PubMedCrossRef Schubart CD, Sommer IEC, Fusar-Poli P, de Witte L, Kahn RS, Boks MPM. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:51–64.PubMedCrossRef
16.
go back to reference Gururajan A, Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 2016;176:281–90.PubMedCrossRef Gururajan A, Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 2016;176:281–90.PubMedCrossRef
18.
go back to reference Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12: 777804.PubMedPubMedCentralCrossRef Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12: 777804.PubMedPubMedCentralCrossRef
19.
go back to reference Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13: e0195687.PubMedPubMedCentralCrossRef Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13: e0195687.PubMedPubMedCentralCrossRef
20.
go back to reference Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, et al. Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat. 2020;77:1044–51.CrossRef Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, et al. Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat. 2020;77:1044–51.CrossRef
21.
go back to reference Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.PubMedPubMedCentralCrossRef Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.PubMedPubMedCentralCrossRef
22.
23.
go back to reference Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79:549–56.PubMedCrossRef Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79:549–56.PubMedCrossRef
24.
go back to reference Hamilton I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction. 2017;112:1653–7.PubMedCrossRef Hamilton I. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction. 2017;112:1653–7.PubMedCrossRef
25.
go back to reference Farris MS, Shakeel MK, Addington J. Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. Soc Psychiatry Psychiatr Epidemiol. 2020;55:527–37.PubMedCrossRef Farris MS, Shakeel MK, Addington J. Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. Soc Psychiatry Psychiatr Epidemiol. 2020;55:527–37.PubMedCrossRef
26.
go back to reference Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18:12.PubMedCrossRef Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18:12.PubMedCrossRef
27.
go back to reference van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 2013;8: e76690.PubMedPubMedCentralCrossRef van Nierop M, Janssens M, Genetic Risk OUtcome of Psychosis Investigators, Bruggeman R, Cahn W, de Haan L, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 2013;8: e76690.PubMedPubMedCentralCrossRef
28.
go back to reference Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269:107–20.PubMedCrossRef Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269:107–20.PubMedCrossRef
29.
go back to reference Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status. Addict Behav. 2021;121: 106991.PubMedCrossRef Rup J, Freeman TP, Perlman C, Hammond D. Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status. Addict Behav. 2021;121: 106991.PubMedCrossRef
30.
go back to reference Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res. 2022;308: 114347.PubMedCrossRef Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res. 2022;308: 114347.PubMedCrossRef
31.
go back to reference Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
34.
go back to reference Hudson A, Hudson P. Risk factors for cannabis-related mental health harms in older adults: a review. Clin Gerontol. 2021;44:3–15.PubMedCrossRef Hudson A, Hudson P. Risk factors for cannabis-related mental health harms in older adults: a review. Clin Gerontol. 2021;44:3–15.PubMedCrossRef
35.
go back to reference Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29.PubMedCrossRef Walsh Z, Gonzalez R, Crosby K, Thiessen MS, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29.PubMedCrossRef
36.
go back to reference Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov. 2012;7:25–40.PubMedPubMedCentralCrossRef Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov. 2012;7:25–40.PubMedPubMedCentralCrossRef
37.
go back to reference Hanna RC, Perez JM, Ghose S. Cannabis and development of dual diagnoses: a literature review. Am J Drug Alcohol Abuse. 2017;43:442–55.PubMedCrossRef Hanna RC, Perez JM, Ghose S. Cannabis and development of dual diagnoses: a literature review. Am J Drug Alcohol Abuse. 2017;43:442–55.PubMedCrossRef
39.
go back to reference Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18:374.PubMedPubMedCentralCrossRef Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18:374.PubMedPubMedCentralCrossRef
40.
go back to reference Lichenstein SD. THC, CBD, and anxiety: a review of recent findings on the anxiolytic and anxiogenic effects of cannabis’ primary cannabinoids. Curr Addict Rep. 2022;9:473–85.PubMedPubMedCentralCrossRef Lichenstein SD. THC, CBD, and anxiety: a review of recent findings on the anxiolytic and anxiogenic effects of cannabis’ primary cannabinoids. Curr Addict Rep. 2022;9:473–85.PubMedPubMedCentralCrossRef
41.
go back to reference Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc B Biol Sci. 2012;367:3364–78.CrossRef Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc B Biol Sci. 2012;367:3364–78.CrossRef
42.
go back to reference Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 1990;100:558–9.PubMedCrossRef Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 1990;100:558–9.PubMedCrossRef
43.
go back to reference Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence. Clin Transl Sci. 2022;16:10–30.PubMedPubMedCentralCrossRef Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence. Clin Transl Sci. 2022;16:10–30.PubMedPubMedCentralCrossRef
44.
go back to reference Han K, Wang J-Y, Wang P-Y, Peng Y-C-H. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Res. 2024;339: 116049.PubMedCrossRef Han K, Wang J-Y, Wang P-Y, Peng Y-C-H. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Res. 2024;339: 116049.PubMedCrossRef
45.
go back to reference Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219–26.PubMedPubMedCentralCrossRef Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219–26.PubMedPubMedCentralCrossRef
46.
go back to reference Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259.PubMedPubMedCentralCrossRef Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259.PubMedPubMedCentralCrossRef
47.
go back to reference Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med Lond. 2022;2:139.PubMedPubMedCentralCrossRef Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med Lond. 2022;2:139.PubMedPubMedCentralCrossRef
49.
go back to reference Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25:121–30.PubMedCrossRef Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25:121–30.PubMedCrossRef
50.
go back to reference Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry. 2022;83:42111.CrossRef Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry. 2022;83:42111.CrossRef
52.
go back to reference Bahorik AL, Sterling SA, Campbell CI, Weisner C, Ramo D, Satre DD. Medical and non-medical marijuana use in depression: longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. J Affect Disord. 2018;241:8–14.PubMedPubMedCentralCrossRef Bahorik AL, Sterling SA, Campbell CI, Weisner C, Ramo D, Satre DD. Medical and non-medical marijuana use in depression: longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization. J Affect Disord. 2018;241:8–14.PubMedPubMedCentralCrossRef
53.
go back to reference Lucatch AM, Kloiber SM, Meyer JH, Rizvi SJ, George TP. Effects of extended cannabis abstinence in major depressive disorder. Can J Addict. 2020;11:33–41.CrossRef Lucatch AM, Kloiber SM, Meyer JH, Rizvi SJ, George TP. Effects of extended cannabis abstinence in major depressive disorder. Can J Addict. 2020;11:33–41.CrossRef
54.
go back to reference Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsychol Soc. 2021;27:648–60.PubMedCrossRef Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsychol Soc. 2021;27:648–60.PubMedCrossRef
55.
go back to reference Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T, et al. Cannabidiol as a treatment for mood disorders: a systematic review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique. Can J Psychiatry Rev Can Psychiatry. 2020;65:213–27.CrossRef Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T, et al. Cannabidiol as a treatment for mood disorders: a systematic review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique. Can J Psychiatry Rev Can Psychiatry. 2020;65:213–27.CrossRef
56.
go back to reference Silote GP, Sartim A, Sales A, Eskelund A, Guimarães FS, Wegener G, et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J Chem Neuroanat. 2019;98:104–16.PubMedCrossRef Silote GP, Sartim A, Sales A, Eskelund A, Guimarães FS, Wegener G, et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J Chem Neuroanat. 2019;98:104–16.PubMedCrossRef
57.
go back to reference Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57–64.PubMedCrossRef Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57–64.PubMedCrossRef
58.
go back to reference Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy. 2007;2:29.PubMedPubMedCentralCrossRef Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy. 2007;2:29.PubMedPubMedCentralCrossRef
59.
go back to reference van Rossum I, Boomsma M, Tenback D, Reed C, van Os J, Board EA. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197:35–40.PubMedCrossRef van Rossum I, Boomsma M, Tenback D, Reed C, van Os J, Board EA. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis. 2009;197:35–40.PubMedCrossRef
60.
go back to reference Agrawal A, Nurnberger JI Jr, Lynskey MT, Bipolar Genome Study. Cannabis involvement in individuals with bipolar disorder. Psychiatry Res. 2011;185:459–61.PubMedCrossRef Agrawal A, Nurnberger JI Jr, Lynskey MT, Bipolar Genome Study. Cannabis involvement in individuals with bipolar disorder. Psychiatry Res. 2011;185:459–61.PubMedCrossRef
61.
go back to reference Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord. 2006;95:103–10.PubMedCrossRef Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord. 2006;95:103–10.PubMedCrossRef
62.
go back to reference Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60:733–40.PubMedCrossRef Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60:733–40.PubMedCrossRef
63.
go back to reference Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA. Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Interv Psychiatry. 2016;10:36–44.PubMedCrossRef Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA. Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Interv Psychiatry. 2016;10:36–44.PubMedCrossRef
64.
go back to reference Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoact Drugs. 1998;30:171–7.CrossRef Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoact Drugs. 1998;30:171–7.CrossRef
65.
go back to reference Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as an antidepressant. Depression. 1996;4:77–80.PubMedCrossRef Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as an antidepressant. Depression. 1996;4:77–80.PubMedCrossRef
66.
go back to reference Healey C, Peters S, Kinderman P, McCracken C, Morriss R. Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: a qualitative study. J Affect Disord. 2009;113:118–26.PubMedCrossRef Healey C, Peters S, Kinderman P, McCracken C, Morriss R. Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: a qualitative study. J Affect Disord. 2009;113:118–26.PubMedCrossRef
67.
go back to reference Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293–300.PubMedCrossRef Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293–300.PubMedCrossRef
68.
go back to reference Gruber SA, Sagar KA, Dahlgren MK, Olson DP, Centorrino F, Lukas SE. Marijuana impacts mood in bipolar disorder: a pilot study. Ment Health Subst Use. 2012;5:228–39.PubMedPubMedCentralCrossRef Gruber SA, Sagar KA, Dahlgren MK, Olson DP, Centorrino F, Lukas SE. Marijuana impacts mood in bipolar disorder: a pilot study. Ment Health Subst Use. 2012;5:228–39.PubMedPubMedCentralCrossRef
69.
go back to reference Sagar KA, Dahlgren MK, Racine MT, Dreman MW, Olson DP, Gruber SA. Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS One. 2016;11: e0157060.PubMedPubMedCentralCrossRef Sagar KA, Dahlgren MK, Racine MT, Dreman MW, Olson DP, Gruber SA. Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS One. 2016;11: e0157060.PubMedPubMedCentralCrossRef
70.
go back to reference Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.PubMedCrossRef Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.PubMedCrossRef
71.
go back to reference Pinto JV, Crippa JAS, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior É de M, Santana da Rosa G, et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study: Le cannabidiol comme traitement d’appoint de la dépression bipolaire aiguë: une étude pilote. Can J Psychiatry Rev Can Psychiatr. 2024;69:242–51. Pinto JV, Crippa JAS, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior É de M, Santana da Rosa G, et al. Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study: Le cannabidiol comme traitement d’appoint de la dépression bipolaire aiguë: une étude pilote. Can J Psychiatry Rev Can Psychiatr. 2024;69:242–51.
73.
go back to reference Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018;43:80–102.PubMedCrossRef Hill MN, Campolongo P, Yehuda R, Patel S. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018;43:80–102.PubMedCrossRef
74.
go back to reference Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3:CD002795. Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3:CD002795.
75.
go back to reference Lewis C, Roberts NP, Gibson S, Bisson JI. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11: 1709709.PubMedPubMedCentralCrossRef Lewis C, Roberts NP, Gibson S, Bisson JI. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11: 1709709.PubMedPubMedCentralCrossRef
76.
go back to reference Kondev V, Winters N, Patel S. Cannabis use and posttraumatic stress disorder comorbidity: epidemiology, biology and the potential for novel treatment approaches. Int Rev Neurobiol. 2021;157:143–93.PubMedCrossRef Kondev V, Winters N, Patel S. Cannabis use and posttraumatic stress disorder comorbidity: epidemiology, biology and the potential for novel treatment approaches. Int Rev Neurobiol. 2021;157:143–93.PubMedCrossRef
77.
go back to reference Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76:1174–80.PubMedPubMedCentralCrossRef Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76:1174–80.PubMedPubMedCentralCrossRef
79.
go back to reference Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293–306.PubMedCrossRef Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293–306.PubMedCrossRef
80.
go back to reference Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45:3181–9.PubMedPubMedCentralCrossRef Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45:3181–9.PubMedPubMedCentralCrossRef
82.
go back to reference LaFrance EM, Glodosky NC, Bonn-Miller M, Cuttler C. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298–304.PubMedCrossRef LaFrance EM, Glodosky NC, Bonn-Miller M, Cuttler C. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298–304.PubMedCrossRef
84.
go back to reference O’Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med. 2017;167:332–40.PubMedCrossRef O’Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med. 2017;167:332–40.PubMedCrossRef
85.
go back to reference Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol. 2013;168:1456–70.PubMedPubMedCentralCrossRef Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol. 2013;168:1456–70.PubMedPubMedCentralCrossRef
87.
go back to reference Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27.PubMedCrossRef Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27.PubMedCrossRef
88.
go back to reference Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30:271–80.PubMedCrossRef Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30:271–80.PubMedCrossRef
89.
go back to reference Elsaid S, Le Foll B. The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. Neuropsychopharmacology. 2020;45:229–30.PubMedCrossRef Elsaid S, Le Foll B. The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders. Neuropsychopharmacology. 2020;45:229–30.PubMedCrossRef
90.
go back to reference Devi M, Bamrah PK, Goyal R, Choudhary M, Chopra H. Insights on the emerging therapeutic potential of terpenoids as anti-inflammatory agents: a scoping review. J Bio-X Res. 2024;7:0006. Devi M, Bamrah PK, Goyal R, Choudhary M, Chopra H. Insights on the emerging therapeutic potential of terpenoids as anti-inflammatory agents: a scoping review. J Bio-X Res. 2024;7:0006.
92.
go back to reference Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437:57–67.PubMedCrossRef Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437:57–67.PubMedCrossRef
93.
go back to reference Hassan W, Noreen H, Castro-Gomes V, Mohammadzai I, Batista Teixeira Da Rocha J, Landeira-Fernandez J. Association of oxidative stress with psychiatric disorders. Curr Pharm Des. 2016;22:2960–74.PubMedCrossRef Hassan W, Noreen H, Castro-Gomes V, Mohammadzai I, Batista Teixeira Da Rocha J, Landeira-Fernandez J. Association of oxidative stress with psychiatric disorders. Curr Pharm Des. 2016;22:2960–74.PubMedCrossRef
94.
go back to reference Gallily R, Yekhtin Z, Hanuš LO. Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol. Pharmacol Pharm. 2015;6:75–85.CrossRef Gallily R, Yekhtin Z, Hanuš LO. Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol. Pharmacol Pharm. 2015;6:75–85.CrossRef
95.
go back to reference Berthold EC, Kamble SH, Kanumuri SRR, Kuntz MA, Senetra AS, Chiang YH, et al. Comparative pharmacokinetics of commercially available cannabidiol isolate, broad-spectrum, and full-spectrum products. Eur J Drug Metab Pharmacokinet. 2023;48:427–35.PubMedCrossRef Berthold EC, Kamble SH, Kanumuri SRR, Kuntz MA, Senetra AS, Chiang YH, et al. Comparative pharmacokinetics of commercially available cannabidiol isolate, broad-spectrum, and full-spectrum products. Eur J Drug Metab Pharmacokinet. 2023;48:427–35.PubMedCrossRef
96.
go back to reference Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.PubMedPubMedCentralCrossRef Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.PubMedPubMedCentralCrossRef
97.
go back to reference Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav. 2005;81:285–99.PubMedPubMedCentralCrossRef Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav. 2005;81:285–99.PubMedPubMedCentralCrossRef
98.
go back to reference Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9:736–50.PubMedCrossRef Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9:736–50.PubMedCrossRef
99.
go back to reference Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2:233–8.PubMedCrossRef Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2:233–8.PubMedCrossRef
100.
go back to reference Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? Lancet Psychiatry. 2017;4:643–8.PubMedCrossRef Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? Lancet Psychiatry. 2017;4:643–8.PubMedCrossRef
101.
go back to reference Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7:865–74.PubMedPubMedCentralCrossRef Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7:865–74.PubMedPubMedCentralCrossRef
102.
go back to reference Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry. 2010;197:285–90.PubMedCrossRef Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry. 2010;197:285–90.PubMedCrossRef
104.
go back to reference Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879–85.PubMedPubMedCentralCrossRef Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879–85.PubMedPubMedCentralCrossRef
105.
go back to reference Batalla A, Maat A. Cannabis use and psychosis susceptibility: a call to action. Eur Neuropsychopharmacol. 2021;54:70–1.PubMedCrossRef Batalla A, Maat A. Cannabis use and psychosis susceptibility: a call to action. Eur Neuropsychopharmacol. 2021;54:70–1.PubMedCrossRef
106.
go back to reference Leadbeater BJ, Ames ME, Linden-Carmichael AN. Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. Addiction. 2019;114:278–93.PubMedCrossRef Leadbeater BJ, Ames ME, Linden-Carmichael AN. Age-varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults. Addiction. 2019;114:278–93.PubMedCrossRef
107.
go back to reference Piyanova A, Lomazzo E, Bindila L, Lerner R, Albayram O, Ruhl T, et al. Age-related changes in the endocannabinoid system in the mouse hippocampus. Mech Ageing Dev. 2015;150:55–64.PubMedCrossRef Piyanova A, Lomazzo E, Bindila L, Lerner R, Albayram O, Ruhl T, et al. Age-related changes in the endocannabinoid system in the mouse hippocampus. Mech Ageing Dev. 2015;150:55–64.PubMedCrossRef
109.
go back to reference Befort K. Interactions of the opioid and cannabinoid systems in reward: insights from knockout studies. Front Pharmacol. 2015;6:6.PubMedPubMedCentral Befort K. Interactions of the opioid and cannabinoid systems in reward: insights from knockout studies. Front Pharmacol. 2015;6:6.PubMedPubMedCentral
110.
go back to reference Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30:680–95.PubMedCrossRef Egerton A, Allison C, Brett RR, Pratt JA. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev. 2006;30:680–95.PubMedCrossRef
112.
go back to reference Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36:277–96.PubMedPubMedCentralCrossRef Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36:277–96.PubMedPubMedCentralCrossRef
113.
go back to reference Sagar KA, Gruber SA. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry. 2018;30:251–67.PubMedPubMedCentralCrossRef Sagar KA, Gruber SA. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry. 2018;30:251–67.PubMedPubMedCentralCrossRef
114.
go back to reference Hawke LD, Wilkins L, Henderson J. Early cannabis initiation: substance use and mental health profiles of service-seeking youth. J Adolesc. 2020;83:112–21.PubMedCrossRef Hawke LD, Wilkins L, Henderson J. Early cannabis initiation: substance use and mental health profiles of service-seeking youth. J Adolesc. 2020;83:112–21.PubMedCrossRef
115.
go back to reference Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health [Internet]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2023. Report No.: HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health [Internet]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2023. Report No.: HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). https://​www.​samhsa.​gov/​data/​report/​2022-nsduh-annual-national-report.
117.
119.
go back to reference Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, Oppenheimer H, et al. A chronic low dose of Delta(9)-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med. 2017;23:782–7.PubMedCrossRef Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, Oppenheimer H, et al. A chronic low dose of Delta(9)-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat Med. 2017;23:782–7.PubMedCrossRef
120.
go back to reference Feliszek M, Bindila L, Lutz B, Zimmer A, Bilkei-Gorzo A, Schlicker E. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:603–12.PubMedCrossRef Feliszek M, Bindila L, Lutz B, Zimmer A, Bilkei-Gorzo A, Schlicker E. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:603–12.PubMedCrossRef
121.
go back to reference Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26:496–506.PubMedCrossRef Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26:496–506.PubMedCrossRef
122.
go back to reference Sagar KA, Dahlgren MK, Gonenc A, Racine MT, Dreman MW, Gruber SA. The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation. Dev Cogn Neurosci. 2015;16:84–92.PubMedPubMedCentralCrossRef Sagar KA, Dahlgren MK, Gonenc A, Racine MT, Dreman MW, Gruber SA. The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation. Dev Cogn Neurosci. 2015;16:84–92.PubMedPubMedCentralCrossRef
123.
go back to reference Dahlgren MK, Sagar KA, Racine MT, Dreman MW, Gruber SA. Marijuana use predicts cognitive performance on tasks of executive function. J Stud Alcohol Drugs. 2016;77:298–208.PubMedPubMedCentralCrossRef Dahlgren MK, Sagar KA, Racine MT, Dreman MW, Gruber SA. Marijuana use predicts cognitive performance on tasks of executive function. J Stud Alcohol Drugs. 2016;77:298–208.PubMedPubMedCentralCrossRef
124.
go back to reference Dahlgren M, Gonenc A, Sagar K, Smith R, Lambros A, El-Abboud C, et al. White matter integrity in medical cannabis patients: increased fractional anisotropy after three months of treatment. Biol Psychiatry. 2021;89:S280–1.CrossRef Dahlgren M, Gonenc A, Sagar K, Smith R, Lambros A, El-Abboud C, et al. White matter integrity in medical cannabis patients: increased fractional anisotropy after three months of treatment. Biol Psychiatry. 2021;89:S280–1.CrossRef
125.
go back to reference Orr JM, Paschall CJ, Banich MT. Recreational marijuana use impacts white matter integrity and subcortical (but not cortical) morphometry. Neuroimage Clin. 2016;12:47–56.PubMedPubMedCentralCrossRef Orr JM, Paschall CJ, Banich MT. Recreational marijuana use impacts white matter integrity and subcortical (but not cortical) morphometry. Neuroimage Clin. 2016;12:47–56.PubMedPubMedCentralCrossRef
126.
go back to reference Gruber SA, Silveri MM, Dahlgren MK, Yurgelun-Todd D. Why so impulsive? White matter alterations are associated with impulsivity in chronic marijuana smokers. Exp Clin Psychopharmacol. 2011;19:231–42.PubMedPubMedCentralCrossRef Gruber SA, Silveri MM, Dahlgren MK, Yurgelun-Todd D. Why so impulsive? White matter alterations are associated with impulsivity in chronic marijuana smokers. Exp Clin Psychopharmacol. 2011;19:231–42.PubMedPubMedCentralCrossRef
127.
go back to reference Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology. 2014;231:1455–65.PubMedCrossRef Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology. 2014;231:1455–65.PubMedCrossRef
128.
go back to reference Jacobus J, Squeglia LM, Infante MA, Bava S, Tapert SF. White matter integrity pre- and post marijuana and alcohol initiation in adolescence. Brain Sci. 2013;3:396–414.PubMedPubMedCentralCrossRef Jacobus J, Squeglia LM, Infante MA, Bava S, Tapert SF. White matter integrity pre- and post marijuana and alcohol initiation in adolescence. Brain Sci. 2013;3:396–414.PubMedPubMedCentralCrossRef
129.
go back to reference Wolfe D, Corace K, Butler C, Rice D, Skidmore B, Patel Y, et al. Impacts of medical and non-medical cannabis on the health of older adults: findings from a scoping review of the literature. PLoS One. 2023;18: e0281826.PubMedPubMedCentralCrossRef Wolfe D, Corace K, Butler C, Rice D, Skidmore B, Patel Y, et al. Impacts of medical and non-medical cannabis on the health of older adults: findings from a scoping review of the literature. PLoS One. 2023;18: e0281826.PubMedPubMedCentralCrossRef
130.
go back to reference Vacaflor BE, Beauchet O, Jarvis GE, Schavietto A, Rej S. Mental health and cognition in older cannabis users: a review. Can Geriatr J. 2020;23:242–9.PubMedPubMedCentralCrossRef Vacaflor BE, Beauchet O, Jarvis GE, Schavietto A, Rej S. Mental health and cognition in older cannabis users: a review. Can Geriatr J. 2020;23:242–9.PubMedPubMedCentralCrossRef
132.
go back to reference Kepner WE, Han BH, Nguyen D, Han SS, Lopez FA, Palamar JJ. Past-month binge drinking and cannabis use among middle-aged and older adults in the United States, 2015–2019—PubMed. Alcohol. 2023;107:32–7.PubMedCrossRef Kepner WE, Han BH, Nguyen D, Han SS, Lopez FA, Palamar JJ. Past-month binge drinking and cannabis use among middle-aged and older adults in the United States, 2015–2019—PubMed. Alcohol. 2023;107:32–7.PubMedCrossRef
135.
136.
go back to reference Halladay J, Petker T, Fein A, Munn C, MacKillop J. Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. Syst Rev. 2018;7:106.PubMedPubMedCentralCrossRef Halladay J, Petker T, Fein A, Munn C, MacKillop J. Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. Syst Rev. 2018;7:106.PubMedPubMedCentralCrossRef
137.
go back to reference Sholler DJ, Strickland JC, Spindle TR, Weerts EM, Vandrey R. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol. 2021;26: e12968.PubMedCrossRef Sholler DJ, Strickland JC, Spindle TR, Weerts EM, Vandrey R. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol. 2021;26: e12968.PubMedCrossRef
138.
go back to reference Matheson J, Bourgault Z, Le Foll B. Sex Differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: a scoping review. Biomolecules. 2022;12:1462.PubMedPubMedCentralCrossRef Matheson J, Bourgault Z, Le Foll B. Sex Differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: a scoping review. Biomolecules. 2022;12:1462.PubMedPubMedCentralCrossRef
139.
go back to reference Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I. Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manag. 2015;49:223–30.CrossRef Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I. Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manag. 2015;49:223–30.CrossRef
140.
go back to reference Ste-Marie PA, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. 2016;157:2792–7.PubMedCrossRef Ste-Marie PA, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. 2016;157:2792–7.PubMedCrossRef
141.
go back to reference Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43:34–51.PubMedCrossRef Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43:34–51.PubMedCrossRef
142.
go back to reference Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT, Gruber SA. A survey of medical cannabis use during perimenopause and postmenopause. Menopause. 2022;29:1028–36.PubMedPubMedCentralCrossRef Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT, Gruber SA. A survey of medical cannabis use during perimenopause and postmenopause. Menopause. 2022;29:1028–36.PubMedPubMedCentralCrossRef
143.
go back to reference Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008;65:1269–74.PubMedCrossRef Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008;65:1269–74.PubMedCrossRef
144.
go back to reference Agrawal A, Nelson EC, Bucholz KK, Tillman R, Grucza RA, Statham DJ, et al. Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study. Lancet Psychiatry. 2017;4:706–14.PubMedPubMedCentralCrossRef Agrawal A, Nelson EC, Bucholz KK, Tillman R, Grucza RA, Statham DJ, et al. Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study. Lancet Psychiatry. 2017;4:706–14.PubMedPubMedCentralCrossRef
145.
go back to reference Agrawal A, Lynskey MT. Cannabis Controversies: how genetics can inform the study of comorbidity. Addict Abingdon Engl. 2014;109:360–70.CrossRef Agrawal A, Lynskey MT. Cannabis Controversies: how genetics can inform the study of comorbidity. Addict Abingdon Engl. 2014;109:360–70.CrossRef
146.
go back to reference Smith RT, Gruber SA. Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions. Front Psychiatry. 2023;13: 1055481.PubMedPubMedCentralCrossRef Smith RT, Gruber SA. Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions. Front Psychiatry. 2023;13: 1055481.PubMedPubMedCentralCrossRef
148.
go back to reference Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 2020;48:1008–17.PubMedPubMedCentralCrossRef Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 2020;48:1008–17.PubMedPubMedCentralCrossRef
149.
go back to reference Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes. Drug Metab Dispos. 2022;50:351–60.PubMedPubMedCentralCrossRef Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes. Drug Metab Dispos. 2022;50:351–60.PubMedPubMedCentralCrossRef
150.
go back to reference Malcolm BJ. Should medical cannabis administered by inhalation be allowed for hospitalized patients? Can J Hosp Pharm. 2018;71:211–4. Malcolm BJ. Should medical cannabis administered by inhalation be allowed for hospitalized patients? Can J Hosp Pharm. 2018;71:211–4.
151.
go back to reference Deepak A, Goyal AK, Rath G. Nanofiber in transmucosal drug delivery. J Drug Deliv Sci Technol. 2018;43:379–87.CrossRef Deepak A, Goyal AK, Rath G. Nanofiber in transmucosal drug delivery. J Drug Deliv Sci Technol. 2018;43:379–87.CrossRef
Metadata
Title
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors
Authors
Kelly A. Sagar
Staci A. Gruber
Publication date
04-01-2025
Publisher
Springer International Publishing
Published in
CNS Drugs
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-024-01148-2

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more